Life science investment activity decelerated by 33.6% in the first half of 2022 compared to a year ago and fundraising increased during that time, although at a slower pace, according to a report this week by Newmark.
"Despite a slowdown in investment activity, pricing for life science and R&D assets remains at a record high, hitting $564 per square foot in 1H22," Newmark said in the report.
"Although bidding pools have thinned compared with 2021, investors are still attracted to laboratory assets, in part due to the supply-demand imbalance that still exists in the largest cluster markets."
Want to continue reading?
Become a Free ALM Digital Reader.
Once you are an ALM Digital Member, you’ll receive:
- Breaking commercial real estate news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical coverage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
*May exclude premium content© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
